These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 18513891)

  • 1. [Toll-like receptors].
    Essakalli M; Atouf O; Bennani N; Benseffaj N; Ouadghiri S; Brick C
    Pathol Biol (Paris); 2009 Jul; 57(5):430-8. PubMed ID: 18513891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.
    Makkouk A; Abdelnoor AM
    Immunopharmacol Immunotoxicol; 2009; 31(3):331-8. PubMed ID: 19555209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.
    Kanzler H; Barrat FJ; Hessel EM; Coffman RL
    Nat Med; 2007 May; 13(5):552-9. PubMed ID: 17479101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
    Conroy H; Marshall NA; Mills KH
    Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-like receptors in inflammation of the central nervous system.
    Kong Y; Le Y
    Int Immunopharmacol; 2011 Oct; 11(10):1407-14. PubMed ID: 21600311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptors' two-edged sword: when immunity meets apoptosis.
    Salaun B; Romero P; Lebecque S
    Eur J Immunol; 2007 Dec; 37(12):3311-8. PubMed ID: 18034428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs targeting Toll-like receptors.
    Krishnan J; Lee G; Choi S
    Arch Pharm Res; 2009 Nov; 32(11):1485-502. PubMed ID: 20091261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders.
    Goldman M
    Clin Exp Immunol; 2007 Feb; 147(2):208-16. PubMed ID: 17223960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll like receptors and acute allograft rejection.
    Goldstein DR
    Transpl Immunol; 2006 Dec; 17(1):11-5. PubMed ID: 17157206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells and toll-like receptors in allergy and asthma.
    Duez C; Gosset P; Tonnel AB
    Eur J Dermatol; 2006; 16(1):12-6. PubMed ID: 16436336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond.
    Lahiri A; Das P; Chakravortty D
    Vaccine; 2008 Dec; 26(52):6777-83. PubMed ID: 18835576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptors.
    Dasari P; Nicholson IC; Zola H
    J Biol Regul Homeost Agents; 2008; 22(1):17-26. PubMed ID: 18394314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Innate immunity, receptors for exogenous and endogenous danger patterns in immunopathogenesis of atherosclerosis--part 1: identification of danger signals by innate immunity].
    Krejsek J; Kunes P; Andrýs C; Holická M; Novosad J; Kudlová M; Kolácková M
    Cas Lek Cesk; 2005; 144(12):785-9. PubMed ID: 16389747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic applications of nucleic acids as ligands for Toll-like receptors.
    Panter G; Kuznik A; Jerala R
    Curr Opin Mol Ther; 2009 Apr; 11(2):133-45. PubMed ID: 19330719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic and therapeutic implications of toll-like receptor ligands.
    Hedayat M; Takeda K; Rezaei N
    Med Res Rev; 2012 Mar; 32(2):294-325. PubMed ID: 22383179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors.
    Romagne F
    Drug Discov Today; 2007 Jan; 12(1-2):80-7. PubMed ID: 17198976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of toll-like receptors in human diseases.
    Montero Vega MT; de Andrés Martín A
    Allergol Immunopathol (Madr); 2009; 37(5):252-63. PubMed ID: 19853360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR based therapeutics.
    Dunne A; Marshall NA; Mills KH
    Curr Opin Pharmacol; 2011 Aug; 11(4):404-11. PubMed ID: 21501972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptors and adaptor molecules in liver disease: update.
    Seki E; Brenner DA
    Hepatology; 2008 Jul; 48(1):322-35. PubMed ID: 18506843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of toll-like receptor therapeutics.
    Parkinson T
    Curr Opin Mol Ther; 2008 Feb; 10(1):21-31. PubMed ID: 18228178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.